HIV-1 and tuberculosis infection [4] (multiple letters)
dc.contributor.author | Warren R.M. | |
dc.contributor.author | Van Helden P.D. | |
dc.contributor.author | Sonnenberg A. | |
dc.contributor.author | Godfrey-Faussett P. | |
dc.contributor.author | Glynn J.R. | |
dc.contributor.author | Shearer S. | |
dc.contributor.author | Murray J. | |
dc.date.accessioned | 2011-05-15T15:57:04Z | |
dc.date.available | 2011-05-15T15:57:04Z | |
dc.date.issued | 2002 | |
dc.description.abstract | [No abstract available] | |
dc.description.version | Letter | |
dc.identifier.citation | Lancet | |
dc.identifier.citation | 359 | |
dc.identifier.citation | 9317 | |
dc.identifier.issn | 1406736 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/10190 | |
dc.subject | Africa | |
dc.subject | comorbidity | |
dc.subject | disease association | |
dc.subject | disease course | |
dc.subject | DNA fingerprinting | |
dc.subject | follow up | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus 1 | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | Italy | |
dc.subject | letter | |
dc.subject | lung tuberculosis | |
dc.subject | mining | |
dc.subject | morbidity | |
dc.subject | multidrug resistance | |
dc.subject | population | |
dc.subject | population risk | |
dc.subject | priority journal | |
dc.subject | recurrence risk | |
dc.subject | reinfection | |
dc.subject | relapse | |
dc.subject | Antitubercular Agents | |
dc.subject | HIV Seronegativity | |
dc.subject | HIV Seropositivity | |
dc.subject | HIV-1 | |
dc.subject | Humans | |
dc.subject | Mining | |
dc.subject | Occupational Exposure | |
dc.subject | Recurrence | |
dc.subject | Risk Factors | |
dc.subject | South Africa | |
dc.subject | Tuberculosis, Pulmonary | |
dc.title | HIV-1 and tuberculosis infection [4] (multiple letters) | |
dc.type | Letter |